roxy_nash said:Steady state is the thing most people miss.
That reframing is the part I needed. I will report back once I have actually tried it.
From the other side of the consultation, briefly.
kate.chem said:...but the FDA says semaglutide...
Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.
Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.
anna.melb_AU said:The mechanism that matters here is not stomach emptying, it is central.
This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne concrete data point for the thread. Practical: unopened, refrigerated at 2 to 8°C; in use, refrigerated and used within the preservative-limited window; never frozen; and a visual check every time — a haze that does not settle is a reason to stop, not to wonder.
Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Thread quality here is what the rules are for. Keep it up.